SUNNYVALE, Calif., July 14, 2015 /PRNewswire/ -- Accuray
Incorporated (Nasdaq: ARAY) announced today that studies on the
clinical use of the CyberKnife® System, the only
robotic SBRT system capable of tracking and automatically
correcting for target motion, continue to demonstrate the benefits
of its precise, innovative treatment delivery techniques. More than
30 studies were presented during poster and oral sessions at the
57th Annual Meeting of the American Association of Physicists in
Medicine (AAPM) held in Anaheim,
California, July 12 –
July 16, 2015.
For more information on the CyberKnife System, visit
http://www.accuray.com/solutions/treatment-planning/cyberknife-treatment-planning-system.
Leading academic institutions, hospitals and cancer treatment
centers are adopting the MLC technology and seeing its benefits
in significantly reduced treatment times for a wider range of tumor
types. UPMC CancerCenter, Erasmus MC Cancer Institute and
European CyberKnife Center Munich shared the first presented
results on the use of the InCise™ MLC for the CyberKnife M6™
System. These results showed the device was:
- "Very reliable"
- "Highly accurate"
- "Mechanically stable"
Studies continue to validate CyberKnife System's unparalleled
tumor targeting capabilities. Highlights include:
Two dosimetric studies highlight the CyberKnife System's
precision.
- A study undertaken at UT Southwestern Medical Center compared
the CyberKnife System and linac IMRT plans of patients with
early-stage larynx cancer. Researchers found the CyberKnife System
was better able to reduce the radiation dose to normal tissue in
high-dose regions. Clinicians can have the confidence to deliver an
ablative dose to the tumor while sparing the immediately adjacent
organs at risk.
- A second study showed the CyberKnife Multiplan®
treatment planning system provided better dose conformity and less
dose to critical organs than VMAT stereotactic plans for patients
with localized prostate cancer. The data demonstrated radiation
dose delivery via multiple non-coplanar beams, with the CyberKnife
System leads to unrivaled precision and tissue sparing. This
research was conducted at Medanta - The Medicity hospital in
Gurgaon, Haryana.
"Data presented at AAPM reinforce the benefits of the CyberKnife
System's non-coplanar beam delivery in ensuring maximal dose
distribution precision while minimizing dose to surrounding healthy
tissue and organs," said Calvin
Maurer, Ph.D., vice president and chief technology officer
at Accuray. "With the addition of the MLC, clinicians can
administer these precise treatments to a broader range of patients
significantly faster. The real-world results clinicians are
achieving with the MLC are consistent with those seen in the
technical evaluation site experience reported at AAPM."
Educational Event
Accuray hosted an educational symposium titled, "Precision in
Practice™ with Accuray Technology" featuring Martina Descovich, Ph.D., Assistant Professor,
Division of Physics, Department of Radiation Oncology at UCSF in
San Francisco, California, and
Saiful Huq, Ph.D., DABR, FAAPM,
FInstP, Professor and Director of Medical Physics, Department of
Radiation Oncology at UPMC CancerCenter in Pittsburgh, Pennsylvania, in addition to two
invited presenters on the TomoTherapy® System. Dr.
Descovich discussed the center's clinical experience with an
enhanced Synchrony® Respiratory Tracking System on the
CyberKnife® System and Dr. Huq shared UPMC's experience
with the InCise™ MLC.
About the CyberKnife System
The CyberKnife M6™ Series delivers radiosurgery and stereotactic
body radiation therapy, enabling precise, high-quality dose
distributions to be administered to the patient with extreme
accuracy over a minimum number of treatments, reducing side effects
and preserving patients' quality of life. The system is able to
adjust and automatically stay on target in real-time, accounting
for patient and tumor motion continually throughout the treatment.
CyberKnife is the only robotic radiosurgery system available today
which delivers such high precision treatments for intra- and
extra-cranial disease sites throughout the body.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology
company that develops, manufactures and sells precise, innovative
tumor treatment solutions that set the standard of care with the
aim of helping patients live longer, better lives. The company's
leading-edge technologies deliver the full range of radiation
therapy and radiosurgery treatments. For more information, please
visit www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to clinical applications,
clinical results, patient outcomes, market adoption of the
company's products, including the MLC, and Accuray's leadership
position radiation oncology innovation and technologies.
Forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially from
expectations, including but not limited to the risks detailed under
the heading "Risk Factors" in the company's report on Form 10-K,
filed on August 29, 2014, the
company's reports on Form 10-Q, filed on November 7, 2014, February
6, 2015 and May 7, 2015, and
the company's other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/new-cyberknife-system-data-presented-at-leading-scientific-industry-meeting-300112609.html
SOURCE Accuray Incorporated